319 results about "Oral tablets" patented technology

The present invention relates to new and useful oral tablet compositions which include an immediate release portion having an opioid analgesic and a non-opioid analgesic, providing for a rapid onset of therapeutic effect, and a sustained release portion of an opioid analgesic and a non-opioid analgesic, providing for a relatively longer duration of therapeutic effect. A multilayer oral dosage form containing a sustained release layer, which includes oxycodone and APAP, hydrocodone and APAP, or oxymorphone and APAP, and an immediate release layer containing the same active ingredients as the sustained release layer, is also disclosed. Also disclosed are oral tablet compositions, containing a sustained release core, which includes oxycodone and APAP, hydrocodone and APAP, or oxymorphone and APAP, and an immediate release coating containing the same active ingredients as the sustained release core, are also disclosed. In addition, methods of making and using such oral tablet compositions are disclosed.

Dissolvable oral tablets and mini-bars which contain healthful ingredients. The products contain a multitude of discrete, extruded sections containing different healthful ingredients. A wide variety of active ingredients includes oxygen enhancers, vitamins, enzymes, dehydrated foods, pycnogenols, food supplements, soy proteins, herbs, roots, and mints. The tablets and mini-bars may be prepared by extruding discrete sections and matrix, all containing active ingredients, cutting the resulting shape for the tablet and mini-bar, and coating with dehydrated food. The tablets and mini-bars may supply needed active ingredients following natural disasters or prior to surgery or may be taken for general use. The products may be contained in a thermal insulating wrapper having an inner piece, an outer piece, and a corrugated piece between the inner and outer pieces. The products may be stored in a thermally insulating luminous canteen container having a primary container having a removable cover and a plurality of secondary containers affixed to the outer wall of the primary container, which containers have removable attached covers. The container may be constructed of hypoallergenic thermoplastic rubber, and may contain a compass and a signaling mirror. These containers also hold water and first aid supplies. The canteen containers may be supplied to survivors of natural disasters or used for general utility.

The invention relates to a Chinese medicinal preparation for treating the diabetes, which is prepared from 47 raw material medicaments in part by weight: astragalus, siberian solomonseal rhizome, common yam rhizome, cornus fruit and the like. A preparation method 1 for the Chinese medicinal preparation comprises the following steps: (1) preparing aqueous extract of the raw material medicaments; (2) preparing oral liquid from the aqueous extract; (3) drying and crashing the aqueous extract obtained by the step (1), and passing the powders through a screen to prepare medicament extract powders; and (4) preparing tablets, granules, pills, soluble granules or capsules with the medicament extraction powders. A preparation method 2 for the Chinese medicinal preparation comprises the following steps: (1) drying fresh pig pancreas and grinding the fresh pig pancreas into powders; (2) crushing other raw material medicaments, passing the powder through a screen to prepare medicament powders; (3) uniformly mixing the pig pancreas powders and the medicament powders, disinfecting and sterilizing to obtain raw powders; and (4) preparing oral tablets, granules, pills, soluble granules or capsules with the raw powders. Based on the principle of monarch, subject, assistant and envoy, the medicament of the invention has synergistic effect, addresses both the symptoms and root causes, has better curative effect on the diabetes, and has obvious effect of treating serious diabetes. The raw medicinal materials adopted by the Chinese medicinal preparation are common Chinese medicaments, have low production cost and have no toxic or side effects basically.

A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.

The present invention makes it possible to provide drug-containing coated microparticles for quick-disintegrating oral tablets wherein microparticles containing a drug with an unpleasant taste are coated with a film composed of (1) a pH-independent water-insoluble polymer accounting for 60% or more but less than 80% of the film and (2) a pH-independent water-soluble substance accounting for more than 20% to 40% or less of the film, these microparticles being characterized in that the rate of dissolution of the drug from the drug-containing microparticles is 0% to 10% in one minute and 80% to 100% in 30 minutes, and the average particle diameter is 350 μm or less, in order to realize sufficient control of oral drug dissolution and fast gastrointestinal drug dissolution.

The invention discloses a culture medium for cultivating cordyceps militaris, a preparation method of the culture medium, a culture method of cordyceps militaris and a preparation method of an oral cordyceps militaris tablet. The culture medium for cultivating cordyceps militaris is an aqueous solution and comprises 130 to 140g / L of dry silkworm chrysalis meal, 60 to 65g / L of rice flour, 1.2 to 1.5g / L of potassium dihydrogen phosphate and 0.8 to 1.2g / L of sodium dihydrogen phosphate. The culture method of cordyceps militaris comprises the following steps of inoculation, culture and harvest re-culture. The preparation method of the oral cordyceps militaris tablet comprises the following steps of drying, multiple cold sterilization treatment, crushing, wet granulation and tabletting. Cordyceps militaris cultured by the culture medium provided by the invention has nutrient content far higher than nutrient content of cordyceps militaris cultured by other culture methods, has a golden color, a luster and a heavy fragrance. In the preparation of the dried oral cordyceps militaris tablet, multiple cold sterilization treatment is carried out after drying. Through low-temperature superfine crushing, a cordyceps militaris spore wall breaking effect is guaranteed and a nutrition constituent loss is reduced.

The invention relates to a maca tea oral tablet and a preparation method thereof. The maca tea oral tablet comprises the following materials by weight: 20 to 30 parts of maca, 10 to 15 parts of instant tea powder, 15 to 30 parts of microcrystalline cellulose, 5 to 10 parts of sorbitol, other auxiliary materials, 0.5 to 1 part of magnesium stearate, and 0 to 2 parts of natural perfume, wherein the other auxiliary materials comprises 15 to 30 parts of lactose,1 to 5 parts of sodium carboxymethyl cellulose, 0 to 0.1 part of sucralose, 0 to 30 parts of maltodextrin; maca is ultramicro powder made of fleshy maca root. The preparation method mainly comprises the following steps: preparation of maca powder and instant tea powder, mixing maca powder and instant tea powder, preparation of a soft material, granulation, granule straightening, drying, tabletting, sterilization and packaging. The maca tea oral tablet is improved in taste, has a cool tea flavor, and tastes refreshing and sweet; due to the adoption of maca which is a nutritional ingredient, the maca tea oral tablet has anti-fatigue, refection and memory improving effects, and is easy to absorb and eat due to the form of tablet.

The present invention relates inter alia to the use of selectively moisture-adjusted tabletting material in the preparation of mechanically stable oral tablets which contain at least one hydrate-forming active substance and / or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing oral tablets.

The invention relates to a sanguisorba root general saponin extract, method for preparation and use thereof, characterized in that, a sanguisorba root general saponin extract is provided which contains sanguisorba root general saponin, the percentage by weight is 10-90%, it can be utilized in the preparation of medicinal preparation for treating or preventing human leucocytopenia. The beneficial effects of the invention are, the preparation can be made into multiple doses including oral, tablet and capsule, and it is adapted for leucocytopenia of unknown reasons.

The invention belongs to the field of hygiene and relates to a bacillus subtillus degrading bacterial colony sensing signal and use of bacillus subtillus degrading bacterial colony as an antiseptic, in particular to bacillus subtillus degrading gram-negative bacterial colony sensing signal and the formation of a bacterial biofilm of the bacillus subtillus degrading gram-negative bacterial colony. In the use of the degrading bacterial colony sensing signal, a proper concentration of the bacillus subtillus is 5*102 to 5*104cfu / ml. The bacillus subtillus is further used as antiseptic to inhibit the bacteria such as pseudomonas, agrobacterium, enterobacteriaceae and vibrionaceae. The antiseptic can be ointment for external use, liquid preparation for external use, oral tablet, oral liquid, disinfectant, clearing agents or water quality improving agent. The consistency of the bacillus subtillus serving as the antiseptic is 105 to 106 cfu / g. The use of the bacillus subtillus provided by the invention and the antiseptic inhibit the formation of biofilm of disease-causing bacteria and the growth of bacteria by using microbial quorum-sensing inhibition instead of preventing and sterilizing bacteria by compound which is adopted by most of the conventional antiseptic; therefore, the problem of drug resistance in the antimicrobial process is avoided.

The preparation method of an oral tablet includes the following steps: mixing the active component 2-[(4-methoxy-3-methyl)-2-pyridyl] methyl sulfinyl-5-(1H-pyrrolyl-1-gruop)-1H-benzimidazole, alkaline compound as stabilizing agent and proper medicinal additive, tableting the obtained the above-mentioned mixture to obtain naked tablet, using film-forming material to make first coating and using enteric soluble coating material to make secondary coating so as to obtain the invented tablet.

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

The invention relates to an oral tablet containing rivaroxaban. The tablet is prepared by adopting a powder direct mixing and tabletting method. an inventor solves partial problems and solves the problems of pitted surface, sticking, loosening tablet and disintegration and dissolution rate and stability problems through addition and replacement of a proper additives and a screening experiment, so as to obtain a novel formula of rivaroxaban tablets and a preparation method of the rivaroxaban tablets by adopting the powder direct mixing and tabletting method. Each rivaroxaban tablet comprises the following components by weight: 5-20mg of rivaroxaban, 60-80mg of lactose, 4-6mg of mannitol, 2-4mg of croscarmellose sodium, 1-3mg of citric acid, 0.5-2mg of lauryl sodium sulfate, 3-5mg of carbomer, 3-5mg of povidone K90, 3-5mg of hydroxyl propyl cellulose, 0.5-2mg of magnesium stearate and 0.5-2mg of silicon dioxide.

The invention belongs to the field of medicinal preparations and in particular relates to a Dasatinib dispersoid, a preparation method thereof and an application thereof in preparation of Dasatinib dispersible tablets. Dasatinib solid dispersoid is prepared by using Dasatinib as an active ingredient and is prepared into tablets of different specifications. The Dasatinib solid dispersible tablets overcome the defects of incomplete release of the medicine and low bioavailability caused by that the dispersible common oral tablets are easy to adhere in the medicine releasing process, so that the bioavailability of the Dasatinib medicine can be further improved and the therapeutic effect of the medicine can be effectively exerted. The preparation process is simple, convenient and practical.

The invention discloses a processing method of ultra-micro wall-breaking oral-tablet decoction pieces by traditional Chinese medicines, which mainly comprises the following steps that: pesticide residues are washed by using high pressure after single traditional Chinese medicinal materials are processed and cut in a standardization way, the traditional Chinese medicinal materials are processed into coarse powder after being dried, heavy metal is removed by dipping, then the coarse powder is processed into ultra-micro wall-breaking powder by ultra-micro pulverization, afterwards the powder is sterilized after being combined with the micro-powder of medicinal auxiliary materials with a certain proportion after quality control reaches a standard, and finally, the step of preparing the oral-tablet decoction pieces is finished. According to the processing method of the ultra-micro wall-breaking oral-tablet decoction pieces by the traditional Chinese medicines, the decoction pieces of single traditional Chinese medicines are prepared into a novel preparation of the oral-tablet decoction pieces, which can be directly swallowed without infusion and also has various tastes. According to the preparation, the advantages of ultra-micro powder and an oral tablet preparation are fused, the time of acting can also be controlled, the use quantity of the auxiliary materials is little, the medicine loading quantity is high, and a novel method for modernizing traditional Chinese medicines is initiated.

The invention provides an oral tablet containing trelagliptin succinate and a preparation method thereof. The tablet do not contain flow aids such as micro-powder silica gel and comprises 35-50 percent by weight of trelagliptin succinate, the trelagliptin succinate tablet cores are prepared by tabletting trelagliptin succinate granules and lubricating agents, and filling agents only exist in the tabletting trelagliptin succinate granules. The trelagliptin succinate tablet prepared by the method disclosed by the invention is stable and controllable in quality, the poor phenomena such as low liquidity in the granulation process and phenomena such as sticking, adhesion, tablet capping and layering during tabletting are avoided, and the oral tablet is suitable for commercialized production.

The invention relates to a pazufloxacin mesylate tablet and a preparation method and a detection method thereof, which belong to the technical field of medicines. A medicinal oral tablet with high dissolvability and high stability is prepared by the following steps of: screening the formula components of the pazufloxacin mesylate tablet; and selecting suitable adhesives and adopting specific coating materials. Clinical trials show that the pazufloxacin mesylate tablet has an exact curative effect, a few side effects and high safety.

A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises as active pharmaceutical agent a compound of formula or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are the same or different and are H, C1-6 alkyl (optionally phenyl substituted), C3-5 alkenyl or alkynyl or C3-10 cycloalkyl, or where R3 is as above and R1 and R2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups; X is H, F, Cl, Br, I, OH, C1-6 alkyl or alkoxy, CN, carboxamide, carboxyl or (C1-6 alkyl)carbonyl; A is CH, CH2, CHF, CHCl, CHBr, CHI, CHCH3, C═O, C═S, CSCH3, C═NH, CNH2, CNHCH3, CNHCOOCH3, CNHCN, SO2 or N; B is CH, CH2, CHF, CHCl, CHBr, CHI, C═O, N, NH or NCH3, and n is 0 or 1; and D is CH, CH2, CHF, CHCl, CHBr, CHI, C═O, O, N, NH or NCH3. The agent is. dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm−2 at a solid fraction representative of the tablet. The composition exhibits sustained-release properties effective for treatment of Parkinson's disease. The tablet is optionally coated. Tablets of the invention have improved resistance to attrition or erosion during manufacture, packaging and handling.

The invention provides high-efficiency low-cost influenza oral tablet vaccine and influenza oral slow-release vaccine which can be produced in large amount and preparation methods thereof, relating to a novel influenza oral tablet or oral slow-release vaccine preparation suitable for oral administration and preparation processes thereof and comprising preparation of virus seed banks, production and preparation of vaccine stock solution, addition and freeze-drying of protective agents and excipients, ingredients of the oral tablet or oral slow-release preparation, forming processes and the like. The preparation method refers to that of whole-virus inactivated vaccines, split vaccines and subunit vaccines. The influenza oral vaccine can avoid pains and discomfort caused by injection, imitate route of natural infection, ensure that most surface areas of the mucosa contact the vaccine and arouse mucosal immune response and systemic immune response. As the vaccines are unnecessary to be produced under extremely strict conditions, the cost is lowered, thus relatively reducing the expenses needed due to increase of the amount of required antigens. The oral vaccine is convenient in use and does not need special personnel for inoculation and is convenient for storage and transportation.

The invention relates to the field of pharmaceutic preparations, in particular to a solid dispersion of fidaxomicin serving as a treating medicament for a disease caused by clostridium difficile and a preparation method for the solid dispersion. The fidaxomicin solid dispersion is solid powder obtained by highly dispersing fidaxomicin into enteric-soluble or water-soluble carrier material, so that the solubility of the fidaxomicin at the small intestine part is greatly improved; compared with a commercially available oral tablet, the fidaxomicin solid dispersion has the advantages of good antibacterial effect, long acting time and little side effect. A medicine composition containing the fidaxomicin solid dispersion provided by the invention is high in solubility and high in stability; the preparation process is simple, the quality is stable, and the fidaxomicin solid dispersion is suitable for industrial production.

The invention discloses a method for processing traditional Chinese medicinal ultramicro wall-broken oral tablet slices. The method mainly comprises the steps of standardizing, processing and cutting single traditional Chinese medicinal material, then removing pesticide residues through high-pressure cleaning, drying, processing the cut traditional Chinese medicinal materials into coarse powder, dipping to remove heavy metals, processing the coarse powder into ultramicro wall-broken powder through ultramicro grinding, mixing the ultramicro wall-broken powder with pharmaceutical adjuvant powder according to a certain ratio and sterilizing after reaching the standard of quality control to finally obtain the tablet slices. The new tablet slices are prepared from single traditional Chinese medicinal slice, can be directly swallowed without brewing, have various flavors and integrate the advantages of ultramicro power and oral tablets, so that the effective time can be controlled, the usage amount of the pharmaceutical adjuvants is less, the drug-loading rate is high, and a new method is innovated for the modernization of traditional Chinese medicines.

An oral tablet of roxatidine hydrochloride acetate with agreeable taste features that the acrylic resin kind of polymers as adhesive and the essence are used as part of its raw materials.

The invention is an oral medicine tablet for advancing liver cell growth. Its ingredients and contents are: liver cell growth advancing element 0.05-15%, filler 50-99.9%, stabilizer 0.05-30%, absorption advancer 0-30%, taste modifier 0-20%, pH value buffer 0-25%, HGF element in the oral tablet has a good stability, the taste is well, and it is convenient, and it is easy to be absorbed by mouth mucous.

The present invention discloses a medicine composition containing rhodiola root extract and ginkgo leaf extract for curing angiocardiopathy and cerebrovascular diseases of cerebral apoplexy, coronary heart disease and angina pectoris, etc. Said medicine composition can be made into oral tablet, capsule, granules and injection preparation.

The present invention relates to an oral tablet for delivery of cannabinoids to mucosal surfaces comprising a population of particles and one or more cannabinoids, the population of particles comprising a) directly compressible (DC) sugar alcohol particles and b) non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.

Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.

The present invention relates to veterinary compositions in a form of an orally deliverable tablet, and more particularly to a controlled-release composition that provides sufficiently long duration to permit once daily administration.

The invention discloses an oral tablet containing candesartan cilexetil and benzene sulfonate amlodipine. The oral tablet consists of benzene sulfonate amlodipine, candesartan cilexetil and medicinal auxiliary materials, wherein the medicinal auxiliary materials contain a stabilizing agent and other auxiliary materials such as one or more of a filling agent, a binding agent and a lubricating agent. The tablet containing candesartan cilexetil and benzene sulfonate amlodipine is attractive in surface and stable in quality. The invention also provides a preparation method for the oral tablet; and the process is simple, low in cost and suitable for commercial production.

Extraction of cynanchum bunqei polysaccharide and preparation of its oral tablets pharmaceutics are achieved by: pulverizeing cynanchum bunqei (granular <4mm), Reflux extracting two to three times in 3-10 times alcohol . The extracted liquid is concentrated to recover for other uses. The extracted solid residues was extracted three times in certain ratio 1: 8-20 of materials and water at 80deg.C-100deg.C for 1-3 h, then incorporating the aquatic extracted liquid. The aquatic extracted liquid was concentrated, depositing with alcohol and drying to obtain cynanchum bunqei crude polysaccharide. The aquatic extracted liquid was destarch by enzyming, deproteinizing by chloroform- normal butanol method, depositing with alcohol and drying to get cynanchum bunqei total polysaccharide. The animal testing in vivo and testing in vitro prove that, the polysaccharide and total polysaccharide are capable of preparing pharmaceuticals as componets of immunoregulation fuctions and health-care food such as buccal tablets and oral liquid.

The invention provides a Chinese lizardtail rhizome or herb rootstock total effective fraction extract, which contains Chinese lizardtail rhizome or herb rootstock total lignan and total fatty acid and has the percentage by weight 10-90 percent. The invention further provides a preparation method and application of a Chinese lizardtail rhizome or herb rootstock total effective fraction. The Chinese lizardtail rhizome or herb rootstock total effective fraction extract can be used for preparing an insulin sensitizer medicinal preparation, has a good insulin sensitizing function, can be preparedinto various dosage forms such as oral tablets, capsules and the like, is suitable for treating insulin resistance-relevant diseases (such as type II diabetes, hypertension, obesity, nonalcoholic fatty liver and heart cerebrovascular thrombosis disease), and has the advantages of remarkable curative effect, low price, convenience for using, and the like.